Buratuss® SR Tablet: Each sustained release tablet contains Butamirate Citrate INN 50 mg.
Buratuss® Syrup: Each 5 ml contains Butamirate Citrate INN 7.5 mg.
Buratuss® Paediatric Drops: Each ml contains Butamirate Citrate INN 5 mg.
Buratuss® is a preparation of Butamirate Citrate, used for the symptomatic treatment of non-productive (dry) cough. Butamirate Citrate, is centrally acting cough suppressant which is neither chemically nor pharmacologically related to opium alkaloids. Butamirate Citrate belongs to the anti-cough medicines of central action. It exerts expectorant, moderate bronchodilating and anti-inflammatory action. Butamirate Citrate also increases the spirometry indexes and blood oxygenation. It is safe and non-sedating. The active metabolites of Butamirate Citrate have also antitussive action.
Tablet
Adult: 2-3 tablets daily at 8 to 12 hours intervals.
Adolescents over 12 years old: 1-2 tablets daily.
Syrup
Children (3-6 years): 5 ml 3 times daily.
Children (6-12 years): 10 ml 3 times daily.
Adolescent: 15 ml 3 times daily.
Adult: 15 ml 4 times daily.
Paediatric Drops
Children (1-3 years): 0.75 ml 4 times daily.
Children (2 months-1 year): 0.50 ml 4 times daily.
Avoid use with expectorants.
Overdosage
Accidental overdose with Buratuss® can cause the following symptoms: drowsiness, nausea, vomiting, diarrhea, loss of balance and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.
Tolerance of Buratuss® is good. Adverse reactions such as rash, nausea, diarrhea and vertigo have been observed in a few rare cases, resolving after dose reduction or treatment withdrawal.
Butamirate Citrate suppresses the cough reflex and therefore the concomitant use with expectorants should be avoided, since it may lead to mucus retention in the airways, which increases the risk of bronchospasm and respiratory infections. Consult with doctor if cough persists for more than 7 days (more than 3 days in children younger than 12 years of age).
Use in Specific Populations
Buratuss® should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Buratuss® administration during breast feeding should be carefully weighed against the risks.
Do not store above 30°C. Keep in a dry place. Protect from light and keep out of the reach of children.